Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2023-02-15 Director's Dealing
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-02-15 English
Regulatory Filings 2023
Regulatory Filings
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from JATT Acquisition Corp to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-4. It is a formal communication related to a regulatory filing process, specifically concerning the timing of the effectiveness of a registration statement for securities. The document does not contain financial data, report content, or detailed disclosures typical of financial reports or presentations. It is a regulatory procedural communication. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-02-10 English
S-4/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 6 to a Form S-4 Registration Statement filed with the SEC. Form S-4 is used for registration of securities in connection with business combinations, mergers, or acquisitions. The text includes detailed exhibits related to a Business Combination Agreement and related legal and financial documents. It is a registration statement amendment, not a financial report like an Annual Report or Interim Report. It is not a proxy statement or voting results announcement, nor is it a call transcript or earnings release. The document is a regulatory filing related to a merger transaction but is not itself a merger proxy statement or tender offer filing (which would be classified as MA or TAR). Given the nature of the Form S-4 amendment and the detailed exhibits, this filing fits best under Regulatory Filings (RNS) as it is a general regulatory submission that does not fit other categories more specifically. The document length and content confirm it is not a brief announcement or certification but a substantive regulatory filing. Confidence is high due to clear identification of the form and content.
2023-02-08 English
JATT 13GA
Major Shareholding Notification
2023-02-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.